f) a polypeptide comprising the amino acid sequence encoded by the cDNA of the clone contained in NRRL Deposit No. B-21416;

g) a polypeptide comprising amino acids 1 to 844 of SEQ ID NO:7; and

h) a polypeptide comprising amino acids 850 to 1497 of SEQ ID NO:7.

31. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.

32. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:7.

33. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:9.

34. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises the amino acid sequence encoded by the cDNA of the clone contained in NRRL Deposit No. B-21416.

35. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises the amino acid sequence encoded by the cDNA of the clone contained in ATCC Accession No. 97880.

36. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises the amino acid sequence encoded by the cDNA of the clone contained in ATCC Accession No. 97881.

37. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises amino acids 1 to 844 of SEQ ID NO:7.

38. (Reiterated) The isolated polypeptide of claim 29 wherein the polypeptide comprises amino acids 850 to 1497 of SEQ ID NO:7.

43. (Amended) An isolated polypeptide selected from the group consisting of:

a) a polypeptide consisting of 542 amino acids and encoded by a nucleic acid molecule that hybridizes to the nucleic acid molecule of SEQ ID NO:2 or its complement at 68°C in 0.1X SSC, 0.1% SDS;

b) a polypeptide consisting of 1497 amino acids and encoded by a nucleic acid molecule that hybridizes to the nucleic acid molecule of SEQ ID NO:6 or its complement at 68°C in 0.1X SSC, 0.1% SDS;

c) a polypeptide consisting of 1533 amino acids and encoded by a nucleic acid molecule that hybridizes to the nucleic acid molecule of SEQ ID NO:8 or its complement at 68°C in 0.1X SSC, 0.1% SDS;

d) a polypeptide consisting of 542 amino acids and encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in NRRL Deposit No. B-21426 at 68°C in 0.1X SSC, 0.1% SDS;

e) a polypeptide consisting of 1497 amino acids and encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in ATCC Accession No. 97880 at 68°C in 0.1X SSC, 0.1% SDS; and

f) a polypeptide consisting of 1533 amino acids and encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in ATCC Accession No. 97881 at 68°C in 0.1X SSC, 0.1% SDS,

wherein the presence of the polypeptide in a melanoma cell is associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.

45. (Reiterated) The isolated polypeptide of claim 43 wherein the polypeptide consists of 542 amino acids and is encoded by a nucleic acid molecule that hybridizes to

the nucleic acid molecule of SEQ ID NO:2 or its complement at 68°C in 0.1X SSC, 0.1% SDS.

46. (Reiterated) The isolated polypeptide of claim 43 wherein the polypeptide consists of 1497 amino acids and is encoded by an nucleic acid molecule that hybridizes to the nucleic acid molecule of SEQ ID NO:6 or its complement at 68°C in 0.1X SSC, 0.1% SDS.

47. (Reiterated) The isolated polypeptide of claim 43 wherein the polypeptide consists of 1533 amino acids and is encoded by a nucleic acid molecule that hybridizes to the nucleic acid molecule of SEQ ID NO:8 or its complement at 68°C in 0.1X SSC, 0.1% SDS.

48. (Reiterated) The isolated polypeptide of claim 43 wherein the polypeptide consists of 542 amino acids and is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in NRRL Deposit No. B-21416 at 68°C in 0.1X SSC, 0.1% SDS.

49. (Reiterated) The isolated polypeptide of claim 43 wherein the polypeptide consists of 1497 amino acids and is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in ATCC Accession No. 97880 at 68°C in 0.1X SSC, 0.1% SDS.

50. (Reiterated) The isolated polypeptide of claim 43 wherein the polypeptide consists of 1533 amino acids and is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in ATCC Accession No. 97881 at 68°C in 0.1X SSC, 0.1% SDS.

51. (Amended) An isolated polypeptide encoded by a nucleic acid molecule that comprises at least 30 nucleotides and hybridizes to the nucleic acid molecule of SEQ

ID NO:2 or its complement at 68°C in 0.1X SSC, 0.1% SDS, wherein expression of the polypeptide in a melanoma cell is associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.

52. (Reiterated) An isolated polypeptide encoded by an nucleic acid molecule that comprises at least 30 nucleotides and hybridizes to the nucleic acid molecule of SEQ ID NO:6 or its complement at 68°C in 0.1X SSC, 0.1% SDS, wherein the presence of the polypeptide in a melanoma cell is associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.

53. (Reiterated) An isolated polypeptide encoded by a nucleic acid molecule that comprises at least 30 nucleotides and hybridizes to the nucleic acid molecule of SEQ ID NO:8 or its complement at 68°C in 0.1X SSC, 0.1% SDS, wherein the presence of the polypeptide in a melanoma cell is associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.

54. (Reiterated) An isolated polypeptide encoded by a nucleic acid molecule that comprises at least 30 nucleotides and hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in NRRL Deposit No. B-21416 at 68°C in 0.1X SSC, 0.1% SDS, wherein the presence of the polypeptide in a melanoma cell is associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.

55. (Reiterated) An isolated polypeptide encoded by a nucleic acid molecule that comprises at least 30 nucleotides and hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in ATCC Accession No. 97880 at 68°C in 0.1X SSC, 0.1% SDS, wherein the presence of the polypeptide in a melanoma cell is

associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.

56. (Reiterated) An isolated polypeptide encoded by a nucleic acid molecule that comprises at least 30 nucleotides and hybridizes to a nucleic acid molecule having the sequence of the cDNA of the clone contained in ATCC Accession No. 97881 at 68°C in 0.1X SSC, 0.1% SDS, wherein the presence of the polypeptide in a melanoma cell is associated with decreased metastatic potential of the melanoma cell compared to an otherwise identical melanoma cell that does not express the polypeptide.